Clinuvel Pharmaceuticals Limited Stock Xetra
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded
| Market Cap | 452M 319M 275M 254M 237M 445M 30.29B 2.99B 1.17B 14.74B 1.2B 1.17B 51.05B | P/E Ratio 2026 * |
12.6x | P/E Ratio 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 198M 140M 121M 111M 104M 195M 13.28B 1.31B 512M 6.46B 524M 513M 22.38B | EV / Sales 2026 * |
1.99x | EV / Sales 2027 * | 1.57x |
| Free-Float |
83.79% | Yield 2026 * |
0.68% | Yield 2027 * | 0.89% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 312M | |
| +0.11% | -3.67% | +17.30% | -18.82% | 62.21B | |
| +1.44% | +5.33% | +68.08% | +223.49% | 59.45B | |
| +0.70% | +29.50% | +29.50% | +29.50% | 38.9B | |
| +0.26% | +9.80% | -55.40% | -64.79% | 36.4B | |
| +0.05% | +2.41% | +51.20% | -36.17% | 29.52B | |
| +0.65% | +6.01% | +56.79% | +74.77% | 21.54B | |
| +0.54% | +5.21% | +82.49% | -59.59% | 19.7B | |
| +4.80% | -0.20% | -5.33% | +112.95% | 16.18B | |
| +0.18% | -1.66% | +49.80% | +101.47% | 15.89B | |
| Average | +0.87% | +3.32% | +32.71% | +40.31% | 33.31B | |
| Weighted average by Cap. | +0.79% | +3.50% | +31.09% | +45.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.5M 70.18M 60.61M 55.86M 52.28M 97.98M 6.67B 660M 257M 3.25B 263M 258M 11.24B | 105M 74.31M 64.18M 59.14M 55.36M 104M 7.06B 698M 272M 3.44B 279M 273M 11.9B |
| Net income | 35.94M 25.35M 21.89M 20.17M 18.88M 35.39M 2.41B 238M 92.87M 1.17B 95.12M 93.1M 4.06B | 38.2M 26.94M 23.27M 21.44M 20.07M 37.62M 2.56B 253M 98.72M 1.25B 101M 98.96M 4.32B |
| Net Debt | -254M -179M -155M -142M -133M -250M -17.01B -1.68B -656M -8.28B -672M -657M -28.67B | -286M -202M -174M -161M -150M -282M -19.18B -1.9B -739M -9.34B -757M -741M -32.32B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
